Legend Biotech (NasdaqGS:LEGN) Valuation in Focus Following CARVYKTI Sales Surge and Profit Progress

Legend Biotech (LEGN) just delivered its third quarter results, highlighting a surge in CARVYKTI therapy sales and expanded manufacturing across the U.S. and Europe. The company also narrowed losses ...